Coultreon Biopharma has secured $125 million in Series A funding, primarily from Sofinnova Investments and other notable firms, to advance its drug COL-5671, licensed from Galapagos. Currently in Phase 1 trials, Coultreon aims to initiate Phase 2 trials focused on psoriasis and ulcerative colitis, with preliminary results expected in 2027. The company, which specializes in autoimmune disease treatments, is developing oral therapies that inhibit proteins known as SIKs, particularly SIK3, which they believe could provide broader and more durable control over diseases like ulcerative colitis, Crohn’s disease, and rheumatoid arthritis. CEO Pierre Raboisson emphasizes that this approach could significantly change treatment methods for these conditions.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.biopharmadive.com/news/coultreon-biotech-startup-galapagos-immune-drug-financing/818575/
